Drugs / JNJ-42491293
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01359852 | Dec 2010 → Jul 2011 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-42491293 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01359852 ↗ |
| Modality | Diagnostic / imaging agent | “evaluated as a potential positron emission tomography (PET) ligand for use in imaging studies of the brain” NCT01359852 ↗ |
| Route | Intravenous | “\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection” NCT01359852 ↗ |